Scilex Holding Company

Scilex Holding Company a biopharmaceutical company focuses on acquiring developing and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia which is a form of post-shingles nerve pain. The company also develops SP-102 a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103 which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg) a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics Inc.